$0.07
15.43%
Nasdaq, Fri, Aug 01 2025
ISIN
BMG0360L1000
Symbol
CYTO

Altamira Therapeutics Ltd Stock price

$0.07
-0.00 4.65% 1M
-0.04 33.21% 6M
-0.04 35.02% YTD
-1.03 93.47% 1Y
-166.17 99.96% 3Y
-411.93 99.98% 5Y
-40,959.93 100.00% 10Y
-47,999.93 100.00% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.01 15.43%
ISIN
BMG0360L1000
Symbol
CYTO
Industry

Key metrics

Basic
Market capitalization
$410.0k
Enterprise Value
$770.0k
Net debt
$360.0k
Cash
$70.0k
Shares outstanding
2.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.8 | -
EV/Sales
12.8 | -
EV/FCF
0.2
P/B
0.1
Financial Health
Equity Ratio
83.9%
Return on Equity
-30.7%
ROCE
-10.8%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$60.0k | $0.0
EBITDA
$-620.0k | -
EBIT
$-740.3k | $-9.2m
Net Income
$-290.0k | $-7.3m
Free Cash Flow
$4.7m
Growth (TTM | estimate)
Revenue
-80.7% | -100.0%
EBITDA
97.8% | -
EBIT
97.4% | -391.7%
Net Income
99.1% | -268.2%
Free Cash Flow
138.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,052.8% | -
EBIT
-1,261.2%
Net
-489.6% | -
Free Cash Flow
7,926.4%
More
EPS
$-0.1
FCF per Share
$1.7
Short interest
1.4%
Employees
-
Rev per Employee
-
Show more

Is Altamira Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Altamira Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Altamira Therapeutics Ltd forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Altamira Therapeutics Ltd forecast:

Buy
89%
Hold
11%

Financial data from Altamira Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.06 0.06
81% 81%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
- Research and Development Expense 1.03 1.03
95% 95%
1,717%
-0.62 -0.62
98% 98%
-1,033%
- Depreciation and Amortization 0.12 0.12
71% 71%
200%
EBIT (Operating Income) EBIT -0.74 -0.74
97% 97%
-1,234%
Net Profit -0.29 -0.29
99% 99%
-483%

In millions USD.

Don't miss a Thing! We will send you all news about Altamira Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Thomas Meyer
Founded 2003
Website aurismedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today